Company: CERO
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112619
Chunk: 8

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-19
Form: 10-Q
Item: Item 1
Chunk 8
---
 Balance at February 13, 2024 (Predecessor) 
     5,155,703  
    $4,077,560  
     22,764,764  
    $38,023,784  
     292  
    $-  
    $1,036,557  
    $(43,662,032) 
    $(42,625,475)

See accompanying notes to the condensed consolidated
financial statements

Reflects a 1-for-100 reverse stock split effective January 8, 2025
and 1-for-20 reverse stock split effective June 13, 2025

4

CERO THERAPEUTICS HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW

(Unaudited)

    For the Nine Months ended September 30,  2025  
    For the Period from February 14, 2024 through September 30,  2024  
    For the Period from January 1, 2024 through February 13, 2024 

    (Successor)  
    (Successor)  
    (Predecessor) 
  
    Cash flows from operating activities: 

    Net loss 
    $(15,379,641) 
    $(8,404,104) 
    $(572,211)
  
    Adjustments to reconcile net loss to net cash used in operating activities: 

    Gain from settlement of liabilities with vendors 
     -  
     (589,223) 
     - 
  
    Depreciation expense 
     215,069  
     304,446  
     37,356 
  
    Stock-based compensation 
     836,390  
     1,899,771  
     4,431 
  
    Amortization of right-to-use operating lease asset 
     594,829  
     421,092  
     115,859 
  
    Write off of deferred offering costs 
     500,000  
     -  
     - 
  
    Stock-based inducement expense 
     863,550  
     -  
     - 
  
    Amortization of debt discount 
     -  
     -  
     (1,875)
  
    Foreign currency transaction gain included in other income (expenses)